News
ACAD
18.56
+0.43%
0.08
Weekly Report: what happened at ACAD last week (0311-0315)?
Weekly Report · 19h ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. Granted inducement awards to three new employees on March 11, 2024. Each stock option has an exercise price per share equal to $24.13 per share. The stock options will vest over four years. Acadia is advancing breakthroughs in neuroscience to elevate life.
Barchart · 3d ago
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
NASDAQ · 4d ago
ACADIA Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Dow Jones · 5d ago
ACADIA Pharmaceuticals Price Target Cut to $30.00/Share From $40.00 by Morgan Stanley
Dow Jones · 5d ago
Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $30
Benzinga · 5d ago
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Acadia Pharmaceuticals Inc. Will participate in the UBS Virtual CNS Day on March 18, 2024. The conference will be held virtually. A live webcast of Acadia’s presentation will be available on the company's website. Acadia developed the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis.
Barchart · 5d ago
Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
Seeking Alpha · 5d ago
Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Acadia Pharmaceuticals stock price dropped over 15% after its drug candidate, pimavanserin, failed to meet the primary endpoint in a Phase 3 study in negative symptoms of schizophrenia. The drug will lose patent protection in 2030, raising concerns about Acadia's key asset. The company's drug candidate may impact its revenue growth and future profitability.
Seeking Alpha · 6d ago
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
ACADIA Pharmaceuticals Price Target Cut to $30.19/Share From $38.00 by Citigroup
Dow Jones · 6d ago
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. Fell 11% to $16.72 on Tuesday. Asana reported soft FY25 revenue guidance. ClearOne, Inc., rose 168.4% in the mid-day session. Regulus Therapeutics Inc. Shares rose 74.3% after posting strong quarterly results.
Benzinga · 6d ago
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30.19
Benzinga · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners
The tech-heavy Nasdaq drove Wall Street higher on Tuesday. The Dow Jones Industrial Average was up 0.49% at 38,961.06. Southwest Airlines and Delta Airlines were among the biggest losers on the NYSE. Gold miners Geron, Anglo Gold Fields and Newmont Mining were down.
Reuters · 6d ago
Acadia Pharmaceuticals Becomes Oversold (ACAD)
NASDAQ · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Li-Cycle Holdings, Priority Technology, 3M
Dow Jones Industrial Average was up 0.55% on Tuesday. Top three S&P 500 percentage gainers were Oracle, NVIDIA and 3M. Southwest Airlines and American Airlines Group were among the top three percentage losers. Consumer prices data came in hotter than expected.
Reuters · 6d ago
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
NASDAQ · 6d ago
ACADIA Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 6d ago
ACADIA Pharmaceuticals Price Target Cut to $30.00/Share From $35.00 by RBC Capital
Dow Jones · 6d ago
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bad news for the industry. Delta Air Lines (NYSE:DAL) is down 1.2% with its latest quarterly outlook. American Airlines (NASDAQ:AAL) and Southwest Airlines also lower their 2024 outlooks. Today's stock market news includes what's going on with Arm Holdings and Acadia Pharmaceuticals stock.
Investorplace · 6d ago
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. It also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.